Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells

Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells

Background Patients affected by aggressive B-cell malignancies who are resistant to primary or salvage chemoimmunotherapy have an extremely poor prognosis and limited therapeutic options. Promising therapeutic success has been achieved with the infusion of CD19 chimeric antigen receptor-T cells, but...

Full description

Bibliographic Details
Main Authors: Elisa Cappuzzello, Pierangela Palmerini, Annavera Ventura, Andrea Visentin, Giuseppe Astori, Katia Chieregato, Valentina Mozzo, Omar Perbellini, Maria Chiara Tisi, Livio Trentin, Carlo Visco, Marco Ruggeri, Roberta Sommaggio, Antonio Rosato, Anna Dalla Pietà
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002475.full

Internet

https://jitc.bmj.com/content/9/7/e002475.full

Similar Items